UBE2M promotes malignant phenotypes of prostate cancer through mediating NAA10 neddylation
Open Access
- 19 March 2026
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Prostate cancer (PCa) is a common malignant tumor in men, with a high incidence rate, posing a serious threat to human health and quality of life. Neddylation is a major post-translation modification, which is essential for multiple cellular behaviors. Aberrant neddylation has been implicated in the development and progression of various diseases. The NEDD8-conjugating enzyme UBE2M is frequently overexpressed in multiple types of malignancies and is closely associated with tumor initiation, progression, metastasis, and therapy resistance. However, the potential role of UBE2M in prostate cancer remains unknown. In our study, a bioinformatics analysis and Immunohistochemistry were employed to validate elevated UBE2M expression in prostate cancer compared to adjacent tissues. We assessed the impact of UBE2M on tumor progression using in vitro and in vivo functional experiments, including CCK8, colony formation, transwell assay and several animal models including PCa xenografts were employed to investigate the role of UBE2M in PCa progression. To elucidate the mechanism, we utilized Coimmunoprecipitation, Mass spectrometry analysis and Proximity ligation assay to elucidate the mechanisms by which UBE2M functions in prostate cancer cells. We discovered that UBE2M expression is significantly elevated in prostate cancer tissues compared to adjacent paracancerous tissues, and this high UBE2M expression indicates a poorer prognosis for patients. Functional experiments demonstrated that overexpression of UBE2M promotes the proliferation and migration of prostate cancer cells, whereas knockdown of UBE2M inhibits these malignant phenotypes. Furthermore, we identified that NAA10 undergoes neddylation modification, and elucidated that the RBX1-CUL4A complex acts as the critical E3 ligase responsible for this modification, with the K148 site being the key neddylation site. We further confirmed that UBE2M enhances the protein stability and functional activity of NAA10 by promoting its neddylation. Knockdown of NAA10 significantly suppressed the UBE2M-driven proliferation of prostate cancer cells. This study reveals that UBE2M drives prostate cancer tumorigenesis by facilitating NAA10 neddylation. The online version contains supplementary material available at 10.1186/s12967-026-08001-8.Keywords
Funding Information
- National Natural Science Foundation of China (No. 32570899)
- the Natural Science Foundation of Shandong province (No. ZR2024MH138, ZR2022LZL006)
This publication has 40 references indexed in Scilit:
- Molecular Mechanisms of ARD1 in TumorsCancer Medicine, 2025
- Emerging role of NEDD8-mediated neddylation in age-related metabolic diseasesAgeing Research Reviews, 2024
- Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancerInternational Journal of Biological Macromolecules, 2023
- UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disordersCell Metabolism, 2023
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate CancerEuropean Urology, 2021
- UBC12‐mediated SREBP‐1 neddylation worsens metastatic tumor prognosisInternational Journal of Cancer, 2020
- Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancerEBioMedicine, 2019
- Developmental roles of protein N‐terminal acetylationProteomics, 2015
- Castration-resistant prostate cancer: Adaptive responses in the androgen axisCancer Treatment Reviews, 2014
- Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of ConjugationCell, 2008